menu
    • menu
    [{"orgOrder":0,"company":"Aditxt","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-100","moa":"Pro-inflammatory cytokine","graph1":"Immunology","graph2":"Preclinical","graph3":"Aditxt","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aditxt \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Aditxt \/ Undisclosed"},{"orgOrder":0,"company":"Aditxt","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-100","moa":"Pro-inflammatory cytokine","graph1":"Dermatology","graph2":"Preclinical","graph3":"Aditxt","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aditxt \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Aditxt \/ Undisclosed"},{"orgOrder":0,"company":"Aditxt","sponsor":"Cellvera","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.A.E","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aditxt","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aditxt \/ Aditxt","highestDevelopmentStatusID":"15","companyTruncated":"Aditxt \/ Aditxt"},{"orgOrder":0,"company":"Aditxt","sponsor":"Cellvera","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aditxt","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Aditxt \/ Cellvera","highestDevelopmentStatusID":"15","companyTruncated":"Aditxt \/ Cellvera"},{"orgOrder":0,"company":"Aditxt","sponsor":"Appili Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2024","type":"Agreement","leadProduct":"ATI-1701","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aditxt","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aditxt \/ Aditxt","highestDevelopmentStatusID":"4","companyTruncated":"Aditxt \/ Aditxt"},{"orgOrder":0,"company":"Aditxt","sponsor":"Appili Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2024","type":"Acquisition","leadProduct":"ATI-1701","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aditxt","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aditxt \/ Aditxt","highestDevelopmentStatusID":"4","companyTruncated":"Aditxt \/ Aditxt"},{"orgOrder":0,"company":"Aditxt","sponsor":"Appili Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2025","type":"Termination","leadProduct":"ATI-1701","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aditxt","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aditxt \/ Aditxt","highestDevelopmentStatusID":"4","companyTruncated":"Aditxt \/ Aditxt"},{"orgOrder":0,"company":"Aditxt","sponsor":"Evofem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Aditxt","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Aditxt \/ Aditxt","highestDevelopmentStatusID":"15","companyTruncated":"Aditxt \/ Aditxt"},{"orgOrder":0,"company":"Aditxt","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Preclinical","graph3":"Aditxt","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Aditxt \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Aditxt \/ H.C. Wainwright & Co"}]

    Find Clinical Drug Pipeline Developments & Deals by Aditxt

    Menu

    Aditxt

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aditxt

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Aditxt

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATI-1701

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : Appili Therapeutics

                            Deal Size : $1.2 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.

                            Details : The termination allows Appili to refocus on advancing its pipeline of anti-infectives, including ATI-1701, a next-generation LA vaccine with a targeted, well-characterized mechanism of attenuation.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 30, 2025

                            Lead Product(s) : ATI-1701

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : Appili Therapeutics

                            Deal Size : $1.2 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aditxt

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Aditxt

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATI-1701

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : Appili Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Aditxt Signs Amendment with Appili Therapeutics for September 30 Acquisition Close

                            Details : Aditxt will acquire Appili along with its pipeline, which includes the ATI-1701 vaccine. Currently, the vaccine is undergoing evaluation in preclinical trials for the treatment of tularemia.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            July 25, 2024

                            Lead Product(s) : ATI-1701

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : Appili Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aditxt

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Aditxt

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATI-1701

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : Appili Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.

                            Details : Aditxt will acquire Appili and its pipeline, including ATI-1701, a vaccine in preclinical trials for tularemia treatment.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 02, 2024

                            Lead Product(s) : ATI-1701

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : Appili Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aditxt

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Aditxt

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : L-Lactic Acid,Citric Acid,Potassium Bitartrate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Recipient : Evofem Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the Fi...

                            Details : Through the acquisition of Evofem, Aditxt gains access to its first and only FDA-approved hormone-free contraceptive gel, Phexxi (lactic acid, citric acid, and potassium bitartrate).

                            Product Name : Phexxi

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 12, 2023

                            Lead Product(s) : L-Lactic Acid,Citric Acid,Potassium Bitartrate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Recipient : Evofem Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aditxt

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Aditxt

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Favipiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Cellvera

                            Deal Size : $10.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid – with Right...

                            Details : Under the agreement, Aditxt expands its portfolio to include innovative therapies for infectious diseases by including Avigan (favipiravir), an oral broad-spectrum inhibitor of viral RNA-dependent RNA polymerase.

                            Product Name : Avigan

                            Product Type : Miscellaneous

                            Upfront Cash : $10.0 million

                            April 20, 2023

                            Lead Product(s) : Favipiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Cellvera

                            Deal Size : $10.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Aditxt

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Aditxt

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADI-100

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aditxt’s (Nasdaq: ADTX) Adimune™ Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug...

                            Details : ADI™-100 consists of two DNA molecules, which together restore immune tolerance in autoimmune disease and establish tolerance in allogeneic skin transplantation applied in large skin wounds.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            October 21, 2022

                            Lead Product(s) : ADI-100

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Aditxt

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Aditxt

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Study Phase : Preclinical

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $20.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Aditxt Announces Pricing of $20.0 Million Public Offering

                            Details : The company intends to use the net proceeds for general corporate purposes, which may include research and development expenses for plasmid DNA-based therapeutics, capital expenditures, working capital and general and administrative expenses.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 16, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Preclinical

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $20.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Aditxt

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Aditxt

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADI-100

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Adva...

                            Details : ADI-100 consists of two DNA molecules, which together restore immune tolerance in autoimmune disease and establish tolerance in allogeneic skin transplantation applied in large skin wounds.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 08, 2022

                            Lead Product(s) : ADI-100

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Aditxt

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Aditxt

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Favipiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Cellvera

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Aditxt Signs Revenue-Sharing Agreement with Cellvera for up to $30M, and Hosts a Live Business Update Webinar ...

                            Details : Cellvera holds worldwide rights (except Japan) to a broad spectrum oral antiviral drug targeting COVID-19 and other infectious diseases. Cellvera is focused on developing and commercializing antimicrobial therapies across a broad spectrum infectious dise...

                            Product Name : Avigan

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 05, 2022

                            Lead Product(s) : Favipiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Cellvera

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth